Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita… - World …, 2022 - Wiley Online Library
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …
[HTML][HTML] Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita… - World …, 2022 - ncbi.nlm.nih.gov
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …
[PDF][PDF] Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita… - World …, 2022 - lbpharma.us
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita… - WORLD …, 2022 - iris.univr.it
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita, P Brambilla… - World …, 2022 - cir.nii.ac.jp
抄録< jats: p> According to current evidence and guidelines, continued antipsychotic
treatment is key for preventing relapse in people with schizophrenia‐spectrum disorders, but …
treatment is key for preventing relapse in people with schizophrenia‐spectrum disorders, but …
Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 …
G Ostuzzi, F Bertolini, F Tedeschi… - … : official journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita… - WORLD …, 2022 - iris.unimore.it
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
[PDF][PDF] Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including …
G Ostuzzi, F Bertolini, F Tedeschi… - World …, 2022 - globalmentalhealth.cochrane.org
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita… - WORLD …, 2022 - air.unimi.it
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 …
G Ostuzzi, F Bertolini, F Tedeschi, G Vita… - World …, 2022 - boris.unibe.ch
According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …
preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based …